A requirement for NF-kappaB induction in the production of replication-competent HHV-8 virions.
The gammaherpesvirus human herpesvirus 8 (HHV-8) infects endothelial and B-lymphoid cells and is responsible for the development of Kaposi's sarcoma and primary effusion lymphoma (PEL). In the present study, we demonstrate that the activation of the NF-kappaB pathway during HHV-8 lytic replication is required for the generation of replication-competent virions capable of initiating a de novo infection of endothelial cells. In the HHV-8-positive PEL cell line BCBL-1, tetradecanoyl phorbol acetate (TPA) induction of the lytic cycle activates the NF-kappaB pathway, and this activation requires the induction of the IKKbeta component of the classical IkappaB kinase (IKK) complex. To further investigate the role of NF-kappaB activation in HHV-8 lytic replication, the NF-kappaB super-repressor IkappaBalpha-2NDelta4 was introduced into BCBL-1 cells by retroviral transduction. Expression of IkappaBalpha-2NDelta4 completely abolished NF-kappaB activity, as demonstrated by the loss of NF-kappaB DNA-binding activity and the absence of expression of the endogenous, NF-kappaB-regulated IkappaBalpha gene. NF-kappaB blockade dramatically impaired the ability of HHV-8 to produce infectious particles capable of initiating an effective de novo infection of endothelial EA.hy926 cells, as demonstrated by the lack of viral protein production in the target cells. Diminished infectivity did not appear to be caused by a reduction in virus titer, as demonstrated by equivalent viral DNA content in the supernatant of TPA-stimulated BCBL-1 and BCBL-1/2N4 cells. Although the viral and/or cellular products affected by NF-kappaB inactivation remain to be fully characterized, these data demonstrate an unexpected role for NF-kappaB induction during lytic reactivation in the production of replication-competent HHV-8 virions.
Sgarbanti
Marco
M
Terry Fox Molecular Oncology Group, Lady Davis Institute-Jewish General Hospital, Montreal, Quebec, Canada.
Arguello
Meztli
M
tenOever
Benjamin R
BR
Battistini
Angela
A
Lin
Rongtuan
R
Hiscott
John
J
D019288:Herpesvirus 8, Human / Q000187:drug effects / Q000472:pathogenicity* / Q000502:physiology*; D006801:Humans; D051550:I-kappa B Kinase; D016393:Lymphoma, B-Cell / Q000378:metabolism / Q000473:pathology / Q000821:virology; D016328:NF-kappa B / Q000378:metabolism*; D016066:Pleural Effusion, Malignant / Q000378:metabolism / Q000473:pathology / Q000821:virology; D017346:Protein Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate; D014407:Tumor Cells, Cultured; D014771:Virion / Q000187:drug effects / Q000378:metabolism; D014779:Virus Replication
D016328:NF-kappa B; D017346:Protein Serine-Threonine Kinases; C496559:CHUK protein, human; D051550:I-kappa B Kinase; C496560:IKBKB protein, human; C496565:IKBKE protein, human; D013755:Tetradecanoylphorbol Acetate